Delivery Order SPE2DB24D2013-SPE2DB25FCJXX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,376.58 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packaging) on August 4, 2025, with completion targeted for August 5, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for dapagliflozin 10 mg tablets in a quantity of 30-unit packages, with a ceiling value of $5,581.69. This contract, awarded on August 7, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and carries no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $10,763.89. This firm fixed-price delivery order, which reaches ultimate completion on August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $1,070.46 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packages) with an ultimate completion date of August 15, 2025. This competitively awarded contract, issued on August 14, 2025, utilizes a firm fixed price structure with no set-aside designation. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,756.65 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This firm fixed-price contract was competitively awarded without set-aside designation and is scheduled for completion by July 25, 2025. AmerisourceBergen will perform this delivery from its corporate headquarters in Conshohocken, Pennsylvania, where the company maintains significant pharmaceutical distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $26,330.84, was competitively awarded without set-aside restrictions and carries an ultimate completion date of July 31, 2025. The award represents a child contract issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order contract valued at $2,132.04 by the Defense Logistics Agency (DLA) on August 12, 2025, with an ultimate completion date of August 13, 2025. The contract calls for the delivery of Dapagliflozin 10 mg tablets in a 30-count package, a generic diabetes medication. This delivery order operates under a firm fixed-price structure with no set-aside designation, indicating...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count package) under a firm fixed-price contract valued at $1,722.16. This is a non-set-aside competitive award with an ultimate completion date of August 4, 2025, with performance to take place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $38,360.32 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 5 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, competitively awarded delivery order was issued with no set-aside designation and represents performance at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCJXXDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order by the Defense Logistics Agency on August 18, 2025, for the supply of dapagliflozin 10 mg tablets in quantities of 30 units. The contract carries a firm fixed price ceiling value of $39,193.68 and is scheduled for completion by August 19, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp fulfills critical medical procurement needs for federal defense and healthcare systems, including the Defense Health Agency and U.S. Coast Guard. Dapagliflozin is an oral antidiabetic medication commonly used in military healthcare systems to manage diabetes among service members and beneficiaries. The award reflects no set-aside designation, indicating the contract was competitively awarded through open competition. The place of performance is Conshohocken, Pennsylvania, where the company's corporate office and distribution operations are based.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.2k | 8/18/25 |